AAAAAA

   
Results: 1-9 |
Results: 9
TUMOR-ANTIGEN PEPTIDE-SPECIFIC IMMUNIZATION - PRECLINICAL DATA AND DEVELOPMENT OF A RATIONAL PROTOCOL FOR TREATMENT OF MELANOMA
Authors: GAJEWSKI TF FALLARINO F VOGELZANG N
Citation: Tf. Gajewski et al., TUMOR-ANTIGEN PEPTIDE-SPECIFIC IMMUNIZATION - PRECLINICAL DATA AND DEVELOPMENT OF A RATIONAL PROTOCOL FOR TREATMENT OF MELANOMA, Journal of investigative medicine, 44(7), 1996, pp. 375-375
A CONTROLLED TRIAL OF CASODEX(TM) (BICALUTAMIDE) VS FLUTAMIDE, EACH IN COMBINATION WITH LUTEINIZING-HORMONE-RELEASING HORMONE ANALOG THERAPY IN PATIENTS WITH ADVANCED PROSTATE-CANCER
Authors: SOLOWAY MS SCHELLHAMMER P SHARIFI R VENNER P PATTERSON AL SAROSDY M VOGELZANG N JONES J KOLVENBAG G
Citation: Ms. Soloway et al., A CONTROLLED TRIAL OF CASODEX(TM) (BICALUTAMIDE) VS FLUTAMIDE, EACH IN COMBINATION WITH LUTEINIZING-HORMONE-RELEASING HORMONE ANALOG THERAPY IN PATIENTS WITH ADVANCED PROSTATE-CANCER, European urology, 29, 1996, pp. 105-109
INTERLEUKIN-2 ASSOCIATED LINEAR IGA BULLOUS DERMATOSIS
Authors: TRANVAN A PEZEN DS MEDENICA M MICHELSON GC VOGELZANG N SOLTANI KM
Citation: A. Tranvan et al., INTERLEUKIN-2 ASSOCIATED LINEAR IGA BULLOUS DERMATOSIS, Journal of the American Academy of Dermatology, 35(5), 1996, pp. 865-867
BLADDER-CANCER - INTRODUCTION
Authors: STADLER V VOGELZANG N
Citation: V. Stadler et N. Vogelzang, BLADDER-CANCER - INTRODUCTION, Seminars in oncology, 23(5), 1996, pp. 533-534
MAXIMAL ANDROGEN BLOCKADE FOR PATIENTS WITH METASTATIC PROSTATE-CANCER - OUTCOME OF A CONTROLLED TRIAL OF BICALUTAMIDE VERSUS FLUTAMIDE, EACH IN COMBINATION WITH LUTEINIZING-HORMONE-RELEASING HORMONEANALOGUE THERAPY
Authors: SCHELLHAMMER P SHARIFI R BLOCK N SOLOWAY M VENNER P PATTERSON AL SAROSDY M VOGELZANG N JONES J KOLVENBAG G
Citation: P. Schellhammer et al., MAXIMAL ANDROGEN BLOCKADE FOR PATIENTS WITH METASTATIC PROSTATE-CANCER - OUTCOME OF A CONTROLLED TRIAL OF BICALUTAMIDE VERSUS FLUTAMIDE, EACH IN COMBINATION WITH LUTEINIZING-HORMONE-RELEASING HORMONEANALOGUE THERAPY, Urology, 47(1A), 1996, pp. 54-60
URINARY NUCLEAR MATRIX PROTEIN AS A MARKER FOR TRANSITIONAL-CELL CARCINOMA OF THE URINARY-TRACT
Authors: CARPINITO GA STADLER WM BRIGGMAN JV CHODAK GW CHURCH PA LAMM DL LANGE PH MESSING EM PASCIAK RM RESERVITZ GB ROSS RN RUKSTALIS DB SAROSDY MF SOLOWAY MS THIEL RP VOGELZANG N HAYDEN CL
Citation: Ga. Carpinito et al., URINARY NUCLEAR MATRIX PROTEIN AS A MARKER FOR TRANSITIONAL-CELL CARCINOMA OF THE URINARY-TRACT, The Journal of urology, 156(4), 1996, pp. 1280-1285
GEMCITABINE IN THE TREATMENT OF PATIENTS WITH ADVANCED TRANSITIONAL-CELL CARCINOMA - A PHASE-II STUDY
Authors: KUZEL T STADLER W RAGHAVAN D LEVINE E VOGELZANG N ROTH B DORR FA
Citation: T. Kuzel et al., GEMCITABINE IN THE TREATMENT OF PATIENTS WITH ADVANCED TRANSITIONAL-CELL CARCINOMA - A PHASE-II STUDY, European journal of cancer, 31A, 1995, pp. 1152-1152
A CONTROLLED TRIAL OF BICALUTAMIDE VERSUS FLUTAMIDE, EACH IN COMBINATION WITH LUTEINIZING-HORMONE-RELEASING HORMONE ANALOG THERAPY, IN PATIENTS WITH ADVANCED PROSTATE-CANCER - REPLY
Authors: SCHELLHAMMER P VOGELZANG N JONES J KOLVENBAG G
Citation: P. Schellhammer et al., A CONTROLLED TRIAL OF BICALUTAMIDE VERSUS FLUTAMIDE, EACH IN COMBINATION WITH LUTEINIZING-HORMONE-RELEASING HORMONE ANALOG THERAPY, IN PATIENTS WITH ADVANCED PROSTATE-CANCER - REPLY, Urology, 46(6), 1995, pp. 899-901
A CONTROLLED TRIAL OF BICALUTAMIDE VERSUS FLUTAMIDE, EACH IN COMBINATION WITH LUTEINIZING-HORMONE-RELEASING HORMONE ANALOG THERAPY, IN PATIENTS WITH ADVANCED PROSTATE-CANCER
Authors: SCHELLHAMMER P SHARIFI R BLOCK N SOLOWAY M VENNER P PATTERSON AL SAROSDY M VOGELZANG N JONES J KOLVENBAG G
Citation: P. Schellhammer et al., A CONTROLLED TRIAL OF BICALUTAMIDE VERSUS FLUTAMIDE, EACH IN COMBINATION WITH LUTEINIZING-HORMONE-RELEASING HORMONE ANALOG THERAPY, IN PATIENTS WITH ADVANCED PROSTATE-CANCER, Urology, 45(5), 1995, pp. 745-752
Risultati: 1-9 |